Cost-Effectiveness of the MARS Liver Support System
Author Information
Author(s): Hessel Franz P
Primary Institution: Institute for Health Care Management, University of Duisburg-Essen
Hypothesis
What is the cost-effectiveness of the MARS system in treating patients with acute-on-chronic liver failure?
Conclusion
The MARS system significantly improves survival rates in patients with acute-on-chronic liver failure despite high initial treatment costs.
Supporting Evidence
- The 3-year survival rate after MARS was 52% compared to 17% in controls.
- Incremental costs per life-year gained were 31400 EUR.
- Direct medical costs over 3 years were 40000 EUR per patient treated with MARS.
Takeaway
The MARS system helps people with severe liver problems live longer, even though it costs a lot to use.
Methodology
A clinical cohort trial comparing 33 patients treated with MARS to 46 controls over three years.
Potential Biases
Potential selection bias due to non-randomized design.
Limitations
The study is non-randomized, which may introduce selection bias.
Participant Demographics
Adult patients with acute-on-chronic liver failure and documented alcohol abuse.
Statistical Information
P-Value
0.0035
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website